文献速递MDS 与骨髓增殖性肿瘤贫血与红细胞疾病

UBA1突变型骨髓增生异常综合征的分子与临床特征

Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes.
PubMed 文献 · Blood · 2024-01-01

在375例缺乏MDS定义性突变或WHO疾病分类的男性患者中,数字PCR检出28例(7%)携带UBA1 p.M41T/V/L突变。在代表性MDS队列(n=2027)中靶向测序UBA1,另发现26例患者(1%)携带27个变异,其中可能/致病性12个、意义不明15个。40例可能/致病性变异患者均为男性,63%按WHO 2016标准分类为多系发育异常或单系发育异常MDS,82%(28/34)可回顾性评估的病例具有VEXAS综合征相关诊断或炎症性临床表现。

要点

  • 在缺乏MDS定义性突变的男性MDS患者中,UBA1突变检出率为7%(28/375)。
  • 代表性MDS队列中UBA1可能/致病性变异频率为2%(40/2027),均为男性。
  • 82%(28/34)UBA1突变病例具有VEXAS综合征相关诊断或炎症性临床表现。

核心结论

  • UBA1突变在MDS患者中的 prevalence 支持在MDS管理中系统筛查UBA1。

研究设计与样本

  • 对375例缺乏MDS定义性突变或WHO疾病分类的男性患者进行数字PCR检测UBA1 p.M41T/V/L突变。
  • 对代表性MDS队列(n=2027)进行UBA1靶向测序。
  • 对UBA1突变病例进行回顾性临床评估(可行性范围内)。

主要发现

  • 在375例男性患者中,28例(7%)检出UBA1 p.M41T/V/L突变。
  • 在代表性MDS队列(n=2027)中,26例患者(1%)检出27个UBA1变异,其中可能/致病性12个、意义不明15个。
  • 40例可能/致病性变异患者均为男性,63%按WHO 2016标准分类为MDS伴多系发育异常或MDS伴单系发育异常。
  • 患者中位额外髓系基因突变为1个,常见于TET2(n=12)、DNMT3A(n=10)、ASXL1(n=3)或SF3B1(n=3)。
  • 82%(28/34)UBA1突变病例具有VEXAS综合征相关诊断或炎症性临床表现。

临床怎么用

  • 作者认为,MDS患者中UBA1突变的 prevalence 支持在MDS管理中系统筛查UBA1。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Mutations in UBA1, which are disease-defining for VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome, have been reported in patients diagnosed with myelodysplastic syndromes (MDS). Here, we define the prevalence and clinical associations of UBA1 mutations in a representative cohort of patients with MDS. Digital droplet polymerase chain reaction profiling of a selected cohort of 375 male patients lacking MDS disease-defining mutations or established World Health Organization (WHO) disease classification identified 28 patients (7%) with UBA1 p.M41T/V/L mutations. Using targeted sequencing of UBA1 in a representative MDS cohort (n = 2027), we identified an additional 27 variants in 26 patients (1%), which we classified as likely/pathogenic (n = 12) and of unknown significance (n = 15). Among the total 40 patients with likely/pathogenic variants (2%), all were male and 63% were classified by WHO 2016 criteria as MDS with multilineage dysplasia or MDS with single-lineage dysplasia. Patients had a median of 1 additional myeloid gene mutation, often in TET2 (n = 12), DNMT3A (n = 10), ASXL1 (n = 3), or SF3B1 (n = 3). Retrospective clinical review, where possible, showed that 82% (28/34) UBA1-mutant cases had VEXAS syndrome-associated diagnoses or inflammatory clinical presentation. The prevalence of UBA1 mutations in patients with MDS argues for systematic screening for UBA1 in the management of MDS.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Sirenko M, Bernard E, Creignou M, et al. Molecular and clinical presentation of UBA1-mutated myelodysplastic syndromes. Blood. 2024. PMID: 38687605. doi:10.1182/blood.2023023723

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。